Quick Answer
Amphastar Pharmaceuticals, Inc. reported Operating Income of $140.40 million for fiscal year 2025.
Amphastar Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $140.40M | -31.7% |
| 2024 | $205.42M | +4.3% |
| 2023 | $196.99M | +83.2% |
| 2022 | $107.50M | +53.8% |
| 2021 | $69.89M | +538.0% |
| 2020 | $10.95M | +28187.2% |
| 2019 | -$39.0K | +99.5% |
| 2018 | -$8.62M | -579.5% |
| 2017 | -$1.27M | -108.3% |
| 2016 | $15.38M | +322.9% |
| 2015 | -$6.90M | +61.6% |
| 2014 | -$17.98M | -202.8% |
| 2013 | $17.49M | -31.1% |
| 2012 | $25.40M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.32M | -55.6% | -40.0% |
| June 30, 2025 | $42.18M | -23.6% | +13.1% |
| March 31, 2025 | $37.29M | -22.3% | -34.6% |
| September 30, 2024 | $57.05M | -21.5% | +3.3% |
| June 30, 2024 | $55.22M | +49.7% | +15.0% |
| March 31, 2024 | $48.01M | +43.6% | -33.9% |
| September 30, 2023 | $72.68M | +212.9% | +97.0% |
| June 30, 2023 | $36.90M | +48.6% | +10.4% |
- Amphastar Pharmaceuticals, Inc. showed a decrease of -31.7% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Amphastar Pharmaceuticals, Inc.’s operating income has grown by 452.8% (from $25.40 million to $140.40 million).
- The most recent figure is from Amphastar Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: